RBC keeps Medicis at outperform, ups target

Medicis Pharmaceutical, Inc. was reiterated by RBC Capital Markets analyst Ken Trbovich at outperform, above average risk, with a raised price target of $42, from $35. According to the analyst, there are several reasons to expect upside from Ziana, including the fact that other combination topical acne products have been huge commercial successes generating annual sales in excess of $100 million. Ziana's approval comes earlier than the analyst expected, perhaps making his $30 million estimate for next year seem low. Shares of the Scottsdale, Ariz.-based specialty pharmaceutical company were up $2.49, or 6.81%, at $39.08. (NYSE: MRX)

© 2015 Prospect News.
All content on this website is protected by copyright law in the U.S. and elsewhere. For the use of the person downloading only.
Redistribution and copying are prohibited by law without written permission in advance from Prospect News.
Redistribution or copying includes e-mailing, printing multiple copies or any other form of reproduction.